Controversy swirls around adipose-derived cell therapies for reparative medicine

(Mary Ann Liebert, Inc./Genetic Engineering News) Challenging the US Food and Drug Administration's current approach to evaluating and approving adipose-based cell therapies used in reparative medicine, a group of researchers proposes a new path forward that focuses on patient safety and includes evidence-based medical practice.